The cash deal seeks to strengthen the French drugmaker’s immunization portfolio after it suffered setbacks in clinical trials.
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
Get alerts for these topics
GoKawiil
Tech News